Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance
Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 p...
Gespeichert in:
Veröffentlicht in: | Molecular pharmaceutics 2021-06, Vol.18 (6), p.2218-2232 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2232 |
---|---|
container_issue | 6 |
container_start_page | 2218 |
container_title | Molecular pharmaceutics |
container_volume | 18 |
creator | Qiu, Yingshan Clarke, Maria Wan, Leon T. L Lo, Jason C. K Mason, A. James Lam, Jenny K. W |
description | Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration. |
doi_str_mv | 10.1021/acs.molpharmaceut.0c01242 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2531229065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2531229065</sourcerecordid><originalsourceid>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EgvL4BWR2bFL8LlkiKKWiggrBhk3k2BM1KImDnRSVr8dVSyV2rDyyz1zPHIQuKBlSwuiVNmFYu6pdaF9rA303JIZQJtgeGlApeHLNU7a_q6_FEToO4YMQJiTjh-iIC0KFUnKA3p_brqzLb92VrsGuwPPxZFXpDix-nAk8h_hsARfO41C-PN3gO6jKJfgV_iq7BZ7WrXfLCM_7qnaNjvevrgKvGwOn6KDQVYCz7XmC3u7Hr7cPyex5Mr29mSWaK94laa4tTwUBC8IoSjRVkmoriQKl7UiJvDBEp7kRsshHRhdWFTYlOeGRpEbxE3S5yY2jfPYQuqwug4Gq0g24PmRMcspYSpSMaLpBjXcheCiy1pd1nDqjJFurzaLa7I_abKs29p5vv-nzGuyu89dlBOQGWGd8uN43cet_BP8AG0iOJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2531229065</pqid></control><display><type>article</type><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</creator><creatorcontrib>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</creatorcontrib><description>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.0c01242</identifier><identifier>PMID: 34014665</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>A549 Cells ; Drug Carriers - chemistry ; Gene Silencing ; Humans ; Hydrophobic and Hydrophilic Interactions ; Lung - metabolism ; Peptides - chemistry ; Polyethylene Glycols - chemistry ; Respiratory Tract Diseases - genetics ; Respiratory Tract Diseases - therapy ; RNA, Small Interfering - administration & dosage ; RNA, Small Interfering - genetics ; Solubility ; Transfection - methods</subject><ispartof>Molecular pharmaceutics, 2021-06, Vol.18 (6), p.2218-2232</ispartof><rights>2021 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</citedby><cites>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</cites><orcidid>0000-0003-4129-4810 ; 0000-0003-0411-602X ; 0000-0003-2997-010X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.0c01242$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c01242$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>315,781,785,2766,27078,27926,27927,56740,56790</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34014665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiu, Yingshan</creatorcontrib><creatorcontrib>Clarke, Maria</creatorcontrib><creatorcontrib>Wan, Leon T. L</creatorcontrib><creatorcontrib>Lo, Jason C. K</creatorcontrib><creatorcontrib>Mason, A. James</creatorcontrib><creatorcontrib>Lam, Jenny K. W</creatorcontrib><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</description><subject>A549 Cells</subject><subject>Drug Carriers - chemistry</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Lung - metabolism</subject><subject>Peptides - chemistry</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Respiratory Tract Diseases - genetics</subject><subject>Respiratory Tract Diseases - therapy</subject><subject>RNA, Small Interfering - administration & dosage</subject><subject>RNA, Small Interfering - genetics</subject><subject>Solubility</subject><subject>Transfection - methods</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EgvL4BWR2bFL8LlkiKKWiggrBhk3k2BM1KImDnRSVr8dVSyV2rDyyz1zPHIQuKBlSwuiVNmFYu6pdaF9rA303JIZQJtgeGlApeHLNU7a_q6_FEToO4YMQJiTjh-iIC0KFUnKA3p_brqzLb92VrsGuwPPxZFXpDix-nAk8h_hsARfO41C-PN3gO6jKJfgV_iq7BZ7WrXfLCM_7qnaNjvevrgKvGwOn6KDQVYCz7XmC3u7Hr7cPyex5Mr29mSWaK94laa4tTwUBC8IoSjRVkmoriQKl7UiJvDBEp7kRsshHRhdWFTYlOeGRpEbxE3S5yY2jfPYQuqwug4Gq0g24PmRMcspYSpSMaLpBjXcheCiy1pd1nDqjJFurzaLa7I_abKs29p5vv-nzGuyu89dlBOQGWGd8uN43cet_BP8AG0iOJg</recordid><startdate>20210607</startdate><enddate>20210607</enddate><creator>Qiu, Yingshan</creator><creator>Clarke, Maria</creator><creator>Wan, Leon T. L</creator><creator>Lo, Jason C. K</creator><creator>Mason, A. James</creator><creator>Lam, Jenny K. W</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4129-4810</orcidid><orcidid>https://orcid.org/0000-0003-0411-602X</orcidid><orcidid>https://orcid.org/0000-0003-2997-010X</orcidid></search><sort><creationdate>20210607</creationdate><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><author>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>A549 Cells</topic><topic>Drug Carriers - chemistry</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Lung - metabolism</topic><topic>Peptides - chemistry</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Respiratory Tract Diseases - genetics</topic><topic>Respiratory Tract Diseases - therapy</topic><topic>RNA, Small Interfering - administration & dosage</topic><topic>RNA, Small Interfering - genetics</topic><topic>Solubility</topic><topic>Transfection - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiu, Yingshan</creatorcontrib><creatorcontrib>Clarke, Maria</creatorcontrib><creatorcontrib>Wan, Leon T. L</creatorcontrib><creatorcontrib>Lo, Jason C. K</creatorcontrib><creatorcontrib>Mason, A. James</creatorcontrib><creatorcontrib>Lam, Jenny K. W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiu, Yingshan</au><au>Clarke, Maria</au><au>Wan, Leon T. L</au><au>Lo, Jason C. K</au><au>Mason, A. James</au><au>Lam, Jenny K. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2021-06-07</date><risdate>2021</risdate><volume>18</volume><issue>6</issue><spage>2218</spage><epage>2232</epage><pages>2218-2232</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>34014665</pmid><doi>10.1021/acs.molpharmaceut.0c01242</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-4129-4810</orcidid><orcidid>https://orcid.org/0000-0003-0411-602X</orcidid><orcidid>https://orcid.org/0000-0003-2997-010X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2021-06, Vol.18 (6), p.2218-2232 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_2531229065 |
source | MEDLINE; American Chemical Society Journals |
subjects | A549 Cells Drug Carriers - chemistry Gene Silencing Humans Hydrophobic and Hydrophilic Interactions Lung - metabolism Peptides - chemistry Polyethylene Glycols - chemistry Respiratory Tract Diseases - genetics Respiratory Tract Diseases - therapy RNA, Small Interfering - administration & dosage RNA, Small Interfering - genetics Solubility Transfection - methods |
title | Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T08%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20PEGylated%20KL4%20Peptide%20for%20siRNA%20Delivery%20with%20Improved%20Pulmonary%20Tolerance&rft.jtitle=Molecular%20pharmaceutics&rft.au=Qiu,%20Yingshan&rft.date=2021-06-07&rft.volume=18&rft.issue=6&rft.spage=2218&rft.epage=2232&rft.pages=2218-2232&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.0c01242&rft_dat=%3Cproquest_cross%3E2531229065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2531229065&rft_id=info:pmid/34014665&rfr_iscdi=true |